In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4416-4419

  Idelevich, Evgeny A ^a   Von Eiff, Christof ^a,e   Friedrich, Alexander W ^a   Iannelli, Domenico ^b   Xia, Guoqing ^c   Peters, Georg ^a   Peschel, Andreas ^c   Wanninger, Ingrid ^d,f   Becker, Karsten ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d BIOMÉRIEUX   (France)

^e PFIZER INC   (United States)

^f UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; FOSFOMYCIN; LINEZOLID; METICILLIN; PRF 119; PYRROLE DERIVATIVE; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIOPHAGE; BACTERIUM ISOLATE; BROTH DILUTION; CHIMERA; COAGULASE NEGATIVE STAPHYLOCOCCUS; COLONY FORMING UNIT; CONTROLLED STUDY; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ENDOPEPTIDASES; MICROBIAL SENSITIVITY TESTS; RECOMBINANT PROTEINS; STAPHYLOCOCCUS AUREUS;

EID: 80051828382     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00217-11     Document Type: Article

References (37)

1. Ammerlaan, H S, J A Kluytmans, H F Wertheim, J L Nouwen, and M J Bonten. 2009. Eradication of methicillin-resistant Staphylococcus aureus carriage: A systematic review. Clin. Infect. Dis. 48:922-930.
2. Arthington-Skaggs, B A, et al. 2002. Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob. Agents Chemother. 46:2477-2481. (Pubitemid 34793452)
3. Becker, K., et al. 2005. Thermonuclease gene as a target for specific identification of Staphylococcus intermedius isolates: Use of a PCR-DNA enzyme immunoassay. Diagn. Microbiol. Infect. Dis. 51:237-244. (Pubitemid 40460959)
4. Capparelli, R., et al. 2010. Bacteriophage-resistant Staphylococcus aureus mutant confers broad immunity against staphylococcal infection in mice. PLoS One 5:e11720.
5. Coates, T., R. Bax, and A. Coates. 2009. Nasal decolonization of Staphylococcus aureus with mupirocin: Strengths, weaknesses and future prospects. J. Antimicrob. Chemother. 64:9-15.
6. Deutsches Institut für Normung. 2002. DIN 58940-8. Medical microbiology: susceptibility testing of pathogens to antimicrobial agents. Part 8. Microdilution: general method-specific requirements. Beuth, Berlin, Germany.
7. Endl, J., H P Seidl, F. Fiedler, and K H Schleifer. 1983. Chemical composition and structure of cell wall teichoic acids of staphylococci. Arch. Microbiol. 135:215-223. (Pubitemid 13019993)
8. Fischetti, V A 2010. Bacteriophage endolysins: A novel anti-infective to control Gram-positive pathogens. Int. J. Med. Microbiol. 300:357-362.
9. Gargis, S R, et al. 2010. Inhibition of the activity of both domains of lysostaphin through peptidoglycan modification by the lysostaphin immunity protein. Appl. Environ. Microbiol. 76:6944-6946.
10. Grif, K., M P Dierich, K. Pfaller, P A Miglioli, and F. Allerberger. 2001. In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J. Antimicrob. Chemother. 48:209-217. (Pubitemid 32755281)
11. Grundling, A, and O. Schneewind. 2006. Cross-linked peptidoglycan mediates lysostaphin binding to the cell wall envelope of Staphylococcus aureus. J. Bacteriol. 188:2463-2472.
12. Jones, R N, et al. 2009. Zyvox annual appraisal of potency and spectrum program: Linezolid surveillance program results for 2008. Diagn. Microbiol. Infect. Dis. 65:404-413.
13. Jun, S Y, et al. 2011. Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK. Antimicrob. Agents Chemother. 55:1764-1767.
14. Kumar, J K 2008. Lysostaphin: An antistaphylococcal agent. Appl. Microbiol. Biotechnol. 80:555-561.
15. Loeffler, J M, D. Nelson, and V A Fischetti. 2001. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294:2170-2172. (Pubitemid 33150674)
16. Loessner, M J 2005. Bacteriophage endolysins: Current state of research and applications. Curr. Opin. Microbiol. 8:480-487. (Pubitemid 41021911)
17. Lu, J Z, T. Fujiwara, H. Komatsuzawa, M. Sugai, and J. Sakon. 2006. Cell wall-targeting domain of glycylglycine endopeptidase distinguishes among peptidoglycan cross-bridges. J. Biol. Chem. 281:549-558. (Pubitemid 43671218)
18. Murakami, K., et al. 1991. Identification of methicillin-resistant strains of staphylococci by PCR. J. Clin. Microbiol. 29:2240-2244.
19. O'Flaherty, S., et al. 2005. Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals. Appl. Environ. Microbiol. 71:1836-1842. (Pubitemid 40546101)
20. Patel, J B, R J Gorwitz, and J A Jernigan. 2009. Mupirocin resistance. Clin. Infect. Dis. 49:935-941.
21. Piechowicz, L., K. Garbacz, and J. Galinski. 2008. Staphylococcus aureus of phage type 187 isolated from people occurred to be a genes carrier of enterotoxin C and toxic shock syndrome toxin-1 (TSST-1). Int. J. Hyg. Environ. Health 211:273-282. (Pubitemid 351847854)
22. Rashel, M., et al. 2007. Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage φMR11. J. Infect. Dis. 196:1237-1247. (Pubitemid 47580279)
23. Sass, P, and G. Bierbaum. 2007. Lytic activity of recombinant bacteriophage φ11 and φ12 endolysins on whole cells and biofilms of Staphylococcus aureus. Appl. Environ. Microbiol. 73:347-352. (Pubitemid 46079972)
24. Schindler, C A, and V T Schuhardt. 1964. Lysostaphin: A new bacteriolytic agent for the Staphylococcus. Proc. Natl. Acad. Sci. U. S. A. 51:414-421.
25. Sulakvelidze, A., Z. Alavidze, and J G Morris, Jr. 2001. Bacteriophage therapy. Antimicrob. Agents Chemother. 45:649-659. (Pubitemid 32182003)
26. Tenover, F C, et al. 2007. Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci. J. Clin. Microbiol. 45:2917-2922. (Pubitemid 47417334)
27. Van Rijen, M., M. Bonten, R. Wenzel, and J. Kluytmans. 2008. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst. Rev. 4:CD006216.
28. Von Eiff, C., et al. 2001. Nasal carriage as a source of Staphylococcus aureus bacteremia. N. Engl. J. Med. 344:11-16. (Pubitemid 32064839)
29. Von Eiff, C., et al. 2000. Nationwide German multicenter study on prevalence of antibiotic resistance in staphylococcal bloodstream isolates and comparative in vitro activities of quinupristin-dalfopristin. J. Clin. Microbiol. 38:2819-2823. (Pubitemid 30640556)
30. Von Eiff, C., et al. 2006. Hospital and community-acquired methicillin-resistant Staphylococcus aureus in Germany. Clin. Microbiol. Infect. 12(Suppl. 4):P461.
31. Weidenmaier, C., et al. 2004. Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections. Nat. Med. 10:243-245. (Pubitemid 38667612)
32. Wertheim, H F, et al. 2005. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect. Dis. 5:751-762. (Pubitemid 41688980)
33. Wiesmiller, K., T. Keck, R. Leiacker, and J. Lindemann. 2007. Simultaneous in vivo measurements of intranasal air and mucosal temperature. Eur. Arch. Otorhinolaryngol. 264:615-619. (Pubitemid 46701632)
34. Wilkinson, B J 1997. Biology, p. 1-38. In K. B. Crossley and G. L. Archer (ed.), The staphylococci in human disease. Churchill Livingstone, New York, NY.
35. Wos-Oxley, M L, et al. 2010. A poke into the diversity and associations within human anterior nare microbial communities. ISME J. 4:839-851.
36. Young, R. 1992. Bacteriophage lysis: Mechanism and regulation. Microbiol. Rev. 56:430-481.
37. Zygmunt, W A, H P Browder, and P A Tavormina. 1968. Susceptibility of coagulase-negative staphylococci to lysostaphin and other antibiotics. Appl. Microbiol. 16:1168-1173.